Apollomics Inc. Class A
As of Oct 22, 2026, Apollomics is in Stage 2, the uptrend phase, now in week 11 (since Aug 10, 2026). It closed at $22.00, 24.6% below its 52-week high and above its 200-day average, which is rising.
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is APLM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
APLM among Biotechnology243rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …243 | APLM | Stage 2 · wk 11 | 40 | −6.0% |
Apollomics: quick answers
What stage is Apollomics in?
As of Oct 22, 2026, Apollomics (APLM) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 10, 2026 and is in week 11. What the four stages mean
Is Apollomics in an uptrend?
Yes. Apollomics is in a Stage 2 uptrend. It trades 16.0% above its 200-day average, which is rising.
How far is Apollomics from its 52-week high?
Apollomics closed at $22.00 on Oct 22, 2026, 24.6% below its 52-week high of $29.19. Its 52-week low is $11.61.
How has Apollomics performed over the past year?
As of Oct 22, 2026, Apollomics is down 18.3% over the past year and up 14.0% so far in 2026.
Which sector and industry is Apollomics in?
Apollomics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.